Hollingshead MG - Search Results

1

"Vasocrine" formation of tumor cell-lined vascular spaces: implications for rational design of antiangiogenic therapies.

Rybak SM, Sanovich E, Hollingshead MG, Borgel SD, Newton DL, Melillo G, Kong D, Kaur G, Sausville EA. Rybak SM, et al. Among authors: hollingshead mg. Cancer Res. 2003 Jun 1;63(11):2812-9. Cancer Res. 2003. PMID: 12782586

2

Identification of compounds with preferential inhibitory activity against low-Nm23-expressing human breast carcinoma and melanoma cell lines.

Freije JM, Lawrence JA, Hollingshead MG, De la Rosa A, Narayanan V, Grever M, Sausville EA, Paull K, Steeg PS. Freije JM, et al. Among authors: hollingshead mg. Nat Med. 1997 Apr;3(4):395-401. doi: 10.1038/nm0497-395. Nat Med. 1997. PMID: 9095172

3

Efficacy, pharmacokinetics, and in vivo antiviral activity of UC781, a highly potent, orally bioavailable nonnucleoside reverse transcriptase inhibitor of HIV type 1.

Buckheit RW Jr, Hollingshead M, Stinson S, Fliakas-Boltz V, Pallansch LA, Roberson J, Decker W, Elder C, Borgel S, Bonomi C, Shores R, Siford T, Malspeis L, Bader JP. Buckheit RW Jr, et al. AIDS Res Hum Retroviruses. 1997 Jun 10;13(9):789-96. doi: 10.1089/aid.1997.13.789. AIDS Res Hum Retroviruses. 1997. PMID: 9171223

4

2-Chloroethyl-3-sarcosinamide-1-nitrosourea, a novel chloroethylnitrosourea analogue with enhanced antitumor activity against human glioma xenografts.

Marcantonio D, Panasci LC, Hollingshead MG, Alley MC, Camalier RF, Sausville EA, Dykes DJ, Carter CA, Malspeis L. Marcantonio D, et al. Among authors: hollingshead mg. Cancer Res. 1997 Sep 15;57(18):3895-8. Cancer Res. 1997. PMID: 9307267

5

Antiproliferative activity in vitro and in vivo of the spicamycin analogue KRN5500 with altered glycoprotein expression in vitro.

Burger AM, Kaur G, Hollingshead M, Fischer RT, Nagashima K, Malspeis L, Duncan KL, Sausville EA. Burger AM, et al. Clin Cancer Res. 1997 Mar;3(3):455-63. Clin Cancer Res. 1997. PMID: 9815705

6

Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials.

Johnson JI, Decker S, Zaharevitz D, Rubinstein LV, Venditti JM, Schepartz S, Kalyandrug S, Christian M, Arbuck S, Hollingshead M, Sausville EA. Johnson JI, et al. Br J Cancer. 2001 May 18;84(10):1424-31. doi: 10.1054/bjoc.2001.1796. Br J Cancer. 2001. PMID: 11355958 Free PMC article.

7

Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition.

Dudkin L, Dilling MB, Cheshire PJ, Harwood FC, Hollingshead M, Arbuck SG, Travis R, Sausville EA, Houghton PJ. Dudkin L, et al. Clin Cancer Res. 2001 Jun;7(6):1758-64. Clin Cancer Res. 2001. PMID: 11410517

8

Induction of CYP1A1 in tumor cells by the antitumor agent 2-[4-amino-3-methylphenyl]-5-fluoro-benzothiazole: a potential surrogate marker for patient sensitivity.

Hose CD, Hollingshead M, Sausville EA, Monks A. Hose CD, et al. Mol Cancer Ther. 2003 Dec;2(12):1265-72. Mol Cancer Ther. 2003. PMID: 14707267

9

Sensitivity of renal cell carcinoma to aminoflavone: role of CYP1A1.

Loaiza-Pérez AI, Kenney S, Boswell J, Hollingshead M, Hose C, Linehan WM, Worrell R, Rubinstein L, Sausville EA, Vistica DT. Loaiza-Pérez AI, et al. J Urol. 2004 Apr;171(4):1688-97. doi: 10.1097/01.ju.0000108860.03389.1b. J Urol. 2004. PMID: 15017268

10

The hollow fibre model in cancer drug screening: the NCI experience.

Decker S, Hollingshead M, Bonomi CA, Carter JP, Sausville EA. Decker S, et al. Eur J Cancer. 2004 Apr;40(6):821-6. doi: 10.1016/j.ejca.2003.11.029. Eur J Cancer. 2004. PMID: 15120037

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

134 results

Search Page

Filters